|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A competing risks regression was performed to identify variables associated with HCC recurrence and an interaction term between etiology and maximum AFP category.
|
30362249 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
At least one minor allele carrier of SCD5 gene polymorphisms were related to decreased risk of HCC for AFP cut-point levels > 200 or > 400 ng/ml, respectively.
|
30168096 |
2018 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The novel polymorphisms identified in the promoter region of the AFP gene may be pathologically significant in HCC.
|
17433605 |
2007 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, through monitoring aminotransferase and alpha-fetoprotein, it aims to investigate relationships among HBV genotypes, BCP/PreC mutations and HCC development.
|
21950207 |
2011 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that genetic polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis and may markedly increase the AFP level in Taiwanese patients with HCC.
|
25860955 |
2015 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, rs988574 genotype combined with serum level of AFP had a better prognostic value in HBV-related HCC patients (<i>P</i> = 0.026, HR = 1.75, 95% CI = 1.07-2.85).
|
29100351 |
2017 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Standardized exception points for HCC patients are not awarded to patients with AFP levels > 1000 ng/mL that do not decrease to < 500 ng/mL with treatment.
|
30895482 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein, we present a novel concept for the early diagnosis of HCC based on the combination of Raman frequency shift and intensity change, and developed surface-enhanced Raman scattering (SERS)-based immunochips via AFP-L3%.
|
28770990 |
2017 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Liver fibrosis (cirrhosis; P = 0.0005), age (≥ 49 years; P = 0.0048), platelet count (≤ 115 × 10/mm<sup>3</sup> ; P = 0.0007), α-fetoprotein (≥ 8.0 ng/mL; P = 0.030), type IV collagen (≥ 200 ng/mL; P = 0.043), fibrosis-4 index (≥ 4.14; P = 0.0006), and human leukocyte antigen (HLA)-DQA1/DRB1-SNP (AA genotype; P = 0.0092) were significantly associated with HCC development according to the log-rank test.
|
30160782 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The circulating IGF-II mRNA correlated with the stage of HCC, and its positive rate was 100% in HCC with extrahepatic metastasis and 35.5% in HCC with AFP-negative.
|
16094705 |
2005 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data showed that genotype AA+TA of rs1870377 and genotype CC+TC of rs2071559 were significantly associated with overall survival of HCC patients (P<0.001 and P<0.001, respectively) and remained as significant predictors for OS adjusting for high level of serum AFP (>400 μg/L), existence of portal vein tumor thrombus, and high BCLC stage (HR=0.61; 95% CI, 0.36-0.88; P=0.003 and HR=0.54; 95% CI, 0.40-0.94; P=0.002, respectively).
|
25123269 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aimed at identifying genetic variations in AFP that might be associated with the presence of HCC and cirrhosis among ethnic Indonesians.
|
19968979 |
2010 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We sought to explore the relationship among the ITA.LI.CA prognostic variables (ie tumour stage, functional score based on performance status and Child-Pugh score, and alpha-fetoprotein), treatment selection and survival outcome in HCC patients.
|
31131974 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, carriers of <i>CHI3L1</i> rs6691378 and 10399805 polymorphisms with the variant genotypes GA+AA showed lower levels of alpha-fetoprotein in HCC laboratory status.
|
28260989 |
2017 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By applying the approach to 286 hepatocellular tumour samples, they successfully uncover numerous driver aberration regions across the cancer genome, for example, chromosomes 4p and 5q, which harbour many known hepatocellular cancer related genes such as alpha-fetoprotein (AFP) and ectodermal-neural cortex (ENC1).
|
25014222 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although we did not find any significant results in total analysis (all p>0.05), our stratified data showed that SNP rs9912300 in ACLY gene was significantly associated with overall survival of HCC patients with lower AFP level and SNP rs11871275 in ACACA gene was significantly associated with overall survival of HCC patients with higher AFP level.
|
25735330 |
2015 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis revealed that APRI ≥0.7 was the independent risk factor for HCC recurrence; and AFP ≥20 ng/ml post IFN therapy, as well as HCC recurrence were the independent risk factors of mortality.
|
30527565 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analyses revealed that UGT1A7 L/L and IL-1 beta/-31T/T-511C/C genotypes, the presence of cirrhosis, age >60 years, male sex, and alpha-fetoprotein >20 microg/ml were associated with the presence of HCC (odds ratios, 2.33, 2.67, 4.20, 3.12, 3.09, and 2.90, respectively).
|
15073122 |
2004 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BEST PRACTICE ADVICE 4: HCC surveillance should be performed using ultrasound with or without α-fetoprotein every 6 months.
|
30878469 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with advanced HCC who progressed on or were ineligible to receive sorafenib, Child-Pugh A/B7 and ECOG PS ≤1 were enrolled into Part A (AFP ≥ 1.5× ULN) or Part B (AFP < 1.5× ULN).
|
30963691 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After adjusting AFP level with genetic effects, the participants for HCC risk increased compared to those with AFP level alone (OR = 5.34, 95% CI = 2.57-11.13; P < 0.001 vs. OR = 5.04, 95% CI = 2.46-10.30; P < 0.001).
|
29696820 |
2018 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TERT rs2736098 T allele was also significantly associated with the level of the HCC clinical indicator alpha-fetoprotein (P=0.026).
|
25339005 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
All and 90.3% of the AFP false-negative patients with HCC were correctly diagnosed in these two sets, respectively.
|
31384984 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Elevated TRIM24 level was found in 61.4% HCC samples (51/83) correlating with AFP (P = 0.036), poor differentiation (P = 0.004), intrahepatic metastasis (P = 0.004), recurrence (P = 0.000006), and shorter tumor-free survival time (P = 0.002).
|
24409330 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For small IMCCs (n = 42) and HCCs (n = 72), rim arterial phase hyperenhancement (OR = 9.68), target appearance at DWI (OR = 12.51), alpha fetoprotein (OR = 0.12) and sex (OR = 0.20) were independent predictors in multivariate analysis.
|
29791202 |
2018 |